Associations between cancer and occupational exposures can be dated back into the sixteenth century.
Today, about 200 different chemical compounds and mixtures are known or anticipated to be human carcinogens.
The great majority of human chemical carcinogens require metabolic activation to elicit detrimental effects. The activity of 'xenobiotic metabolizing enzymes' such as cytochrome-P450-dependent monooxygenases, glutathione S-transferases, sulphotransferases and others are required for activation (toxication) of important carcinogens.
Human carcinogens act through a variety of genotoxic and non-genotoxic mechanisms. DNA binding and induction of mutations in cancer-susceptibility genes, such as TP53 and KRAS, are import mechanisms of tumour initiation. In addition, the accompanying ability of many compounds to promote the outgrowth of transformed cell clones has been acknowledged.
The preferential formation of certain stereoisomers during metabolic activation of genotoxic carcinogens can determine the level of DNA damage, the efficiency of DNA repair, and the carcinogenic potency of a compound.
Humans are exposed to mixtures of compounds with different degrees of biological activity. Analysis of compound-specific mutational patterns provides valuable clues on the contribution of individual chemicals (or single classes of chemicals) to the overall biological response to these mixtures observed in certain tissues.
The roles of genetic constitution versus environmental factors in cancer development have been a matter of debate even long before the discovery of 'oncogenes'. Evidence from epidemiological, occupational and migration studies has consistently pointed to environmental factors as the major contributing factors to cancer, so it seems reasonable to discuss the importance of chemical carcinogenesis in the present 'age of cancer genetics'.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Doll, R. & Peto, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66, 1191–1308 (1981). A landmark paper that compiled epidemiological evidence for a predominant role of environmental factors in human cancer.
Kolonel, L. N., Altshuler, D. & Henderson, B. E. The multiethic cohort study: exploring genes, lifestyle and cancer risk. Nature Rev. Cancer 4, 519–527 (2004).
Peto, J. Cancer epidemiology in the last century and the next decade. Nature 411, 390–395 (2001).
Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer. N. Engl. J. Med. 343, 78–85 (2000). Combined data on 44,788 pairs of twins indicate that the environment has the prinicpal role in causing sporadic human cancer.
Czene, K., Lichtenstein, P. & Hemminki, K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int. J. Cancer 99, 260–266 (2002).
Theophrasti Paracelsi von Hohenheim. Von der Bergsucht oder Bergkrankheiten drey Bücher (Sebaldum Mayer, Dilingen, Germany, 1567).
Rostoski, Saupe & Schmorl . Die Bergkrankheit der Erzbergleute in Schneeberg in Sachsen ('Schneeberger Lungenkrebs'). Z. Krebsforsch. 23, 360–384 (1926).
Pirchan, A. & Sikl, H. Cancer of the lung in the miners of Jáchymov (Joachimstal). Report of cases observed in 1929–1930. Am. J. Cancer 16, 681–722 (1932).
Ramazzini, B. De Morbis Artificum Diatriba (Typis Antonii Capponi, Impressoris Episcopalis Supriorum Consensu, 1700).
Hill, J. Cautions Against the Immoderate Use of Snuff. Founded on the Known Qualities of the Tobacco Plant; And the Effects it Must Produce when this Way Taken into the Body: And Enforced by Instances of Persons who have Perished Miserably of Diseases, Occasioned, or Rendered Incurable by its Use (R. Baldwin and J. Jackso, London, 1761).
Pott, P. The Chirurgical Works. Chirurgical Observations Relative to the Cataract, The Polypus of the Nose, The Cancer of the Scrotum, The Different Kinds of Ruptures, and The Mortification of the Toes and Feet Ch. III 60–68 (Hawes, W. Clarke, and R. Collins, London, 1775). Original work of Percivall Pott, who was a surgeon at St. Bartholomew's Hospital London, that contains his seminal report on scrotal cancer in chimney sweeps. This observation raised the first possibility of cancer prevention.
Paris, J. A. Pharmacologica; or the History of Medicinal Substances, with a View to Establish the Art of Prescribing and of Composing Extemporaneous Formulae upon Fixed and Scientific Principles 206–217 (F. & R. Lockwood, New York, 1822).
Volkmann, R. Ueber Theer- und Russkrebs. Berl. Klin. Wochenschr. 11, 218 (1874).
Bell, J. Paraffin epithelioma of the scrotum. Edinb. Med. J. 22, 135–137 (1876).
Hutchinson, J. On some examples of arsenic-keratosis of the skin and of arsenic-cancer. Trans. Path. Soc. London 39, 352–393 (1888).
Rehn, L. Blasengeschwülste bei Fuchsin-Arbeitern. Arch. Klin. Chir. 50, 588–600 (1895). Report of three cases of urinary bladder tumours in the production of 'fuchsin' (magenta), a complex red dyestuff made from aniline and other aromatic amines.
Henry, S. A. Occupational cutaneous cancer attributable to certain chemicals in industry. Br. Med. Bull. 4, 389–401 (1947). Compilation of about 4,000 cases of cutaneous cancer observed in certain factories of Great Britain. Provides interesting insights on the conditions and exposures at work during the first half of the twentieth century.
Yamagiwa, K. & Ichikawa, K. Experimentelle Studie über die Pathogenese der Epithelialgeschwülste. Mitt. Med. Fak. Kaiserl. Univ. Tokio 15, 295–344 (1915).
Kennaway, E. & Hieger, I. Carcinogenic substances and their fluorescence spectra. Br. Med. J. 1, 1044–1046 (1930).
Cook, J. W. et al. Chemical compounds as carcinogenic agents. Am. J. Cancer 29, 219–259 (1937).
Cook, J. W., Hewett, C. L. & Hieger, I. The isolation of a cancer-producing hydrocarbon from coal tar. J. Chem. Soc. 395–405 (1933).
Berenblum, I. & Bonser, G. M. Experimental investigation of 'aniline cancer'. J. Ind. Hyg. Toxicol. 19, 86–92 (1937).
Hueper, W. C. et al. Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J. Ind. Hyg. Toxicol. 20, 46–84 (1938).
Leichtenstern, O. Ueber Harnblasenentzündung und Harnblasengeschwülste bei Arbeitern in Farbfabriken. Dtsch. Med. Wochenschr. 24, 709–713 (1898).
Yoshida, T. Über die serienweise Verfolgung der Veränderungen der Leber der experimentellen Hepatomerzeugung durch o-Aminoazotoluol. Trans. Jap. Path. Soc. 23, 636–638 (1933).
Kinosita, R. Researches on the carcinogenesis of the various chemical substances. (In Japanese). Gann 30, 423–426 (1936).
Wilson, R. H., DeEds, F. & Cox, A. J. Jr. The toxicity and carcinogenic activity of 2-acetaminofluorene. Cancer Res. 1, 595–608 (1941).
U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. 10th Report on Carcinogens [online], <http://ehp.niehs.nih.gov/roc/toc10.html> (Research Triangle Park, North Carolina, USA, 2004).
Miller, E. C. & Miller, J. A. The presence and significance of bound amino azodyes in the livers of rats fed p-dimethylaminoazobenzene. Cancer Res. 7, 468–480 (1947). First demonstration of the covalent binding of a chemical carcinogen to cellular macromolecules such as proteins.
Miller, E. C. Studies on the formation of protein-bound derivatives of 3,4-benzpyrene in the epidermal fraction of mouse skin. Cancer Res. 11, 100–108 (1951).
Miller, E. C. & Miller, J. A. In vivo combinations between carcinogens and tissue constituents and their possible role in carcinogenesis. Cancer Res. 12, 547–556 (1952).
Wheeler, G. P. & Skipper, H. E. Studies with mustards. III. In vivo fixation of C14 from nitrogen mustard-C14H3 in nucleic acid fractions of animal tissues. Arch. Biochem. Biophys. 72, 465–475 (1957). Early paper describing the binding of a carcinogen to DNA in vivo.
Magee, P. N. & Farber, E. Toxic liver injury and carcinogenesis. Methylation of rat-liver nucleic acids by dimethylnitrosamine in vivo. Biochem. J. 83, 114–124 (1962).
Brookes, P. & Lawley, P. D. Evidence for the binding of polynuclear aromatic hydrocarbons to the nucleic acid of mouse skin: relation between carcinogenic power of hydrocarbons and their binding to deoxyribonucleic acid. Nature 202, 781–784 (1964). Seminal paper on the correlation between DNA-binding level and carcinogenicity of six selected polycyclic aromatic hydrocarbons.
Sporn, M. B. & Dingman, C. W. 2-Acetamidofluorene and 3-methylcholanthrene: differences in binding to rat liver deoxyribonucleic acid in vivo. Nature 210, 531–532 (1966).
Dingman, C. W. & Sporn, M. B. The binding of metabolites of aminoazo dyes to rat liver DNA in vivo. Cancer Res. 27, 938–944 (1967).
Auerbach, C. & Robson, J. M. Chemical production of mutations. Nature 157, 302 (1946). The carcinogen 'mustard gas' induced mutations in Drosophila.
Ames, B. N., Durston, W. E., Yamasaki, E. & Lee, F. D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl Acad. Sci. USA 70, 2281–2285 (1973). Bruce Ames established the 'Ames Assay' for testing chemical-induced genotoxicity.
Wiley, F. H. The metabolism of β-naphthylamine J. Biol. Chem. 124, 627–630 (1938).
Boyland, E., Levi, A. A., Mawson, E. H. & Roe, E. Metabolism of polycyclic compounds. 4. Production of a dihydroxy-1:2:5:6-dibenzanthracene from 1:2:5:6-dibenzanthracene. Biochem. J. 35, 184–191 (1941).
Stevenson, E. S., Dobriner, K. & Rhoads, C. P. The metabolism of dimethylaminoazobenzene (Butter Yellow) in rats. Cancer Res. 2, 160–167 (1942).
Mueller, G. C. & Miller, J. A. The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. J. Biol. Chem. 176, 535–544 (1948). First demonstration of microsome-catalysed biotransformation of a chemical carcinogen in vitro.
Conney, A. H., Miller, E. C. & Miller, J. A. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res. 16, 450–459 (1956).
Brodie, B. B. et al. Detoxication of drugs and other foreign compounds by liver microsomes. Science 121, 603–604 (1955).
Omura, T. & Sato, R. A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375–1376 (1962).
Lu, A. Y. H. & Coon, M. J. Role of hemoprotein P-450 in fatty acid ω-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 243, 1331–1332 (1968).
Guengerich, F. P. & Shimada, T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391–407 (1991).
Shimada, T., Oda, Y., Gillam, E. M. J., Guengerich, F. P. & Inoue, K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab. Disp. 29, 1176–1182 (2001).
Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S. & Satoh, T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123, 369–375 (2003).
Cramer, J. W., Miller, J. A. & Miller, J. C. N-Hydroxylation: a new metabolic reaction observed in the rat with the carcinogen 2-acetylaminofluorene. J. Biol. Chem. 235, 885–888 (1960).
Miller, E. C., Miller, J. A. & Hartmann, H. A. N-Hydroxy-2-acetylaminofluorene: a metabolite of 2-acetylaminofluorene with increased carcinogenic activity in the rat. Cancer Res. 21, 815–824 (1961).
DeBraun, J. R., Smith, J. Y. R., Miller, E. C. & Miller, J. A. Reactivity in vivo of the carcinogen N-hydroxy-2-acetylaminofluorene: increase by sulfate ion. Science 167, 184–186 (1970). First evidence that sulphate esters of N -hydroxyarylamines or -amides are the ultimate carcinogenic metabolites of the corresponding parent compounds formed in vivo.
Dipple, A. DNA adducts of chemical carcinogens. Carcinogenesis 16, 437–441 (1995).
Booth, J., Boyland, E. & Sims, P. An enzyme from rat liver catalysing conjugations with glutathione. Biochem. J. 79, 516–524 (1961).
Wartenberg, D, Reyner, D. & Scott, C. S. Trichloroethylene and cancer: epidemiological evidence. Environ. Health Perspect. 108 (Suppl. 2), 161–176 (2000).
Guengerich, F. P. Activations of dihaloalkanes by thiol-dependent mechanisms. J. Biochem. Mol. Biol. 36, 20–27 (2003).
Anders, M. W. & Dekant, W. Glutathione-dependent bioactivation of haloalkenes. Annu. Rev. Pharmacol. Toxicol. 38, 501–537 (1998).
McGregor, D. B., Partensky, C., Wilbourn, J. & Rice, J. M. An IARC evaluation of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans as risk factors in human carcinogenesis. Environ. Health Perspect. 106 (Suppl. 2), 755–760 (1998).
Huff, J., Lucier, G. & Tritscher, A. Carcinogenicity of TCDD: experimental, mechanistic, and epidemiologic evidence. Annu. Rev. Pharmacol. Toxicol. 34, 343–372 (1994).
Piskorska-Pliszczynska, J., Keys, B., Safe, S. & Newman, M. S. The cytosolic receptor binding affinities and AHH induction potencies of 29 polynuclear aromatic hydrocarbons. Toxicol. Lett. 34, 67–74 (1986).
Conney, A. H., Miller, E. C. & Miller, J. A Substrate-induced synthesis and other properties of benzpyrene hydroxylase in rat liver. J. Biol. Chem. 228, 753–766 (1957). Describes BP-mediated induction of arylhydrocarbon hydroxylase in rat liver.
Poland, A., Glover, E. & Kende, A. S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 251, 4936–4946 (1976).
Gu, Y. Z., Hogenesch, J. B. & Bradfield, C. A. The PAS superfamily: sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 40, 519–561 (2000).
Nebert, D. W., Puga, A. & Vasiliou, V. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. NY Acad. Sci. 685, 624–640 (1993).
Gonzalez, F. J. & Fernandez-Salguero, P. The arylhydrocarbon receptor. Studies using the AhR-null mice. Drug Metab. Dispos. 26, 1194–1198 (1998).
Fernandez-Salguero, P. M., Hilbert, D. M., Rudikoff, S., Ward, J. M. & Gonzalez, F. J. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol. 140, 173–179 (1996). Reports that mice deficient for the AhR are fully protected against the toxic effects of TCDD in the liver, thymus, heart, kidney, pancreas, spleen, lymph nodes and uterus.
Andersson, P. et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl Acad. Sci. USA 99, 9990–9995 (2002).
Moennikes, O. et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64, 4707–4710 (2004). Unequivocal proof that the AhR is crucial in mediating the tumour-promoting activities of receptor agonists such as TCDD, polycyclic aromatic hydrocarbons and polychlorinated biphenyls.
Mimura, J. & Fujii-Kuriyama, Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta 1619, 263–268 (2003).
Frueh, F. W., Hayashibara, K. C., Brown, P. O. & Whitlock, J. P. Jr. Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression. Toxicol. Lett. 122, 189–203 (2001).
Puga, A., Maier, A. & Medvedovic, M. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem. Pharmacol. 60, 1129–1142 (2000).
Carlson, D. B. & Perdew, G. H. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J. Biochem. Mol. Toxicol. 16, 317–325 (2002).
Enan, E. & Matsumura, F. Identification of c-Src as the integral component of the cytosolic Ah receptor complex, transducing the signal of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) through the protein phosphorylation pathway. Biochem. Pharmacol. 52, 1599–1612 (1996). The protein kinase SRC is activated in cytosolic liver preparations through attachment to the AhR and upon binding to TCDD.
Luch, A. in The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons (ed. Luch, A.) 1–18 (Imperial College, London, in the press).
Boyland, E. & Levi, A. A. Metabolism of polycyclic compounds. I. Production of dihydroxydihydroanthracene from anthracene. Biochem. J. 29, 2679–2683 (1935).
Boyland, E. & Sims, P. Metabolism of polycyclic compounds. 16. The metabolism of 1:2-dihydronaphthalene and 1:2-epoxy-1:2:3:4-tetrahydronaphthalene. Biochem. J. 77, 175–181 (1960).
Sims, P., Grover, P. L., Swaisland, A., Pal, K. & Hewer, A. Metabolic activation of benzo[a]pyrene proceeds by a diol-epoxide. Nature 252, 326–328 (1974). First experimental evidence that the vicinal 'bay-region' 7,8-dihydrodiol 9,10-epoxide is the ultimate DNA-binding metabolite of the aromatic hydrocarbon BP.
Luch, A. & Baird, W. M. in The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons (ed. Luch, A.) 19–96 (Imperial College, London, in the press).
Gonzalez, F. J. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol. Lett. 120, 199–208 (2001).
Balmain, A. & Pragnell, I. B. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303, 72–74 (1983). Genomic DNA from skin carcinomas of mice sequentially treated with a chemical initiator (7,12-dimethylbenz[ a ]anthracene) and a promotor (12- O -tetradecanoylphorbol-13–acetate) of carcinogenesis contained an activated RAS oncogene and morphologically transformed fibroblasts.
Shimizu, Y. et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA 97, 779–782 (2000). Demonstrates that BP-mediated tumorigenesis in subcutaneous or epidermal mouse tissue requires the presence of a functional AhR.
Klaunig, J. E. & Kamendulis, L. M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 44, 239–267 (2004).
Freudenthal, R. I., Stephens, E. & Anderson, D. P. Determining the potential of aromatic amines to induce cancer in the urinary bladder. Int. J. Toxicol. 18, 353–359 (1999).
Beland, F. A. & Kadlubar, F. F. Formation and persistance of arylamine DNA adducts in vivo. Environ. Health Perspect. 62, 19–33 (1985).
Neumann, H. G., Ambs, S. & Bitsch, A. The role of nongenotoxic mechanisms in arylamine carcinogenesis. Environ. Health Perspect. 102 (Suppl. 6), 173–176 (1994).
Klöhn, P. C. et al. Early resistance to cell death and to onset of the mitochondrial permeability transition during hepatocarcinogenesis with 2-acetylaminofluorene. Proc. Natl Acad. Sci. USA 100, 10014–10019 (2003).
Van Delft, J. H. M. et al. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25, 1265–1276 (2004).
Bombail, V., Moggs, J. G. & Orphanides, G. Perturbation of epigenetic status by toxicants. Toxicol. Lett. 149, 51–58 (2004).
Hartwig, A. et al. Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ. Health Perspect. 110 (Suppl. 5), 797–799 (2002).
McMurray, C. T. & Tainer, J. A. Cancer, cadmium and genome integrity. Nature Genet. 34, 239–241 (2003).
Hughes, M. F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 133, 1–16 (2002).
Kawanishi, S., Hiraku, Y., Murata, M. & Oikawa S. Oxidative damage and repair: the role of metals in site-specific DNA damage with reference to carcinogenesis. Free Radic. Biol. Med. 32, 822–832 (2002).
Beyersmann, D. & Hechtenberg, S. Cadmium, gene regulation, and cellular signalling in mammalian cells. Toxicol. Appl. Pharmacol. 144, 247–261 (1997).
Qian, Y., Castranova, V. & Shi, X. New perspectives in arsenic-induced cell signal transduction. J. Inorg. Biochem. 96, 271–278 (2003).
Kasprzak, K. S., Sunderman, F. W. Jr. & Salnikow, K. Nickel carcinogenesis. Mutat. Res. 533, 67–97 (2003).
Lee, Y. W. et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol. Cell. Biol. 15, 2547–2557 (1995).
Zhang, Q. et al. Inhibition and reversal of nickel-induced transformation by the histone deacetylase inhibitor trichostatin A. Toxicol. Appl. Pharmacol. 192, 201–211 (2003).
Govindarajan, B. et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16Ink4a and activation of MAP kinase. Mol. Med. 8, 1–8 (2002).
Kowara, R. et al. Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas. Mol. Cell. Biochem. 255, 195–202 (2004).
Chen, H. et al. Association of c-myc oncogene overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 175, 260–268 (2001).
Zhao, C. Q., Young, M. R., Diwan, B. A., Coogan, T. P. & Waalkes, M. P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl Acad. Sci. USA 94, 10907–10912 (1997).
Glatt, H. R. in The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons. (ed. Luch, A.) 283–314 (Imperial College, London, in the press).
Ross, J. A. et al. Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res 55, 1039–1044 (1995).
Poirier, M. C. Chemical-induced DNA damage and human cancer risk. Nature Rev. Cancer 4, 630–637 (2004).
Kensler, T. W., Qian, G. S., Chen, J. G. & Groopman, J. D. Translational strategies for cancer prevention in liver. Nature Rev. Cancer 3, 321–329 (2003).
Baertschi, S. W., Raney, K. D., Stone, M. P. & Harris, T. M. Preparation of the 8,9-epoxide of the mycotoxin aflatoxin B1: the ultimate carcinogenic species. J. Am. Chem. Soc. 110, 7929–7931 (1988). Key experiment with chemically synthesized AFB 1 exo -8,9-oxide that provided an unequivocal proof that this epoxide is the DNA-binding metabolite of the mycotoxin.
Guengerich, F. P. et al. Activation and detoxification of aflatoxin B1 . Mutat. Res. 402, 121–128 (1998).
Iyer, R. S. et al. DNA adduction by the potent carcinogen aflatoxin B1: mechanistic studies. J. Am. Chem. Soc. 116, 1603–1609 (1994).
Yang, S. K., McCourt, D. W., Roller, P. P. & Gelboin, H. V. Enzymatic conversion of benzo[a]pyrene leading predominantly to the diol-epoxide r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene through a single enantiomer of r-7,t-8-dihydroxy-7,8-dihydrobenzo[a]pyrene. Proc. Natl Acad. Sci. USA 73, 2594–2598 (1976).
Koreeda, M. et al. Binding of benzo[a]pyrene 7,8-diol-9,10-epoxides to DNA, RNA, and protein of mouse skin occurs with high stereoselectivity. Science 199, 778–780 (1978).
Cheng, S. C., Hilton, B. D., Roman, J. M. & Dipple, A. DNA adducts from carcinogenic and noncarcinogenic enantiomers of benzo[a]pyrene dihydrodiol epoxides. Chem. Res. Toxicol. 2, 334–340 (1989).
Friedberg, E. C. How nucleotide excision repair protects against cancer. Nature Rev. Cancer 1, 22–33 (2001).
Hess, M. T., Gunz, D., Luneva, N., Geacintov, N. E. & Naegeli, H. Base pair conformation-dependent excision of benzo[a]pyrene diol epoxide-guanine adducts by human nucleotide excision repair enzymes. Mol. Cell. Biol. 17, 7069–7076 (1997). Indicates that the efficiency of NER of bulky aromatic hydrocarbon–DNA adducts greatly depends on the stereochemistry and the conformation of the lesion induced.
Geacintov, N. E. et al. NMR solution structures of stereoisomeric covalent polycyclic aromatic carcinogen-DNA adducts: principles, patterns, and diversity. Chem. Res. Toxicol. 10, 111–146 (1997).
Khan, Q. A. & Dipple, A. Diverse chemical carcinogens fail to induce G1 arrest in MCF-7 cells. Carcinogenesis 21, 1611–1618 (2000).
Wang, A. et al. Response of human mammary epithelial cells to DNA damage induced by BPDE: involvement of novel reulatory pathways. Carcinogenesis 24, 225–234 (2003).
Lehmann, A. R. Replication of damaged DNA in mammalian cells: new solutions to an old problem. Mutat. Res. 509, 23–34 (2002).
Ross, J. A. & Nesnow, S. Polycyclic aromatic hydrocarbons: correlation between DNA adducts and ras oncogene mutations. Mutat. Res. 424, 155–166 (1999).
Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459–465 (2003).
Feng, Z. et al. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J. Natl Cancer Inst. 94, 1527–1536 (2002). Codon 12 of KRAS in bronchial epithelial cells is a DNA-binding 'hot spot' of the cigarette smoke carcinogen BP, due to both a preferential binding of anti -BPDE at the first dG in this codon and the inefficient DNA repair that follows.
Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
Hu, W., Feng, Z. & Tang, M. -S. Preferential carcinogen-DNA adduct formation at codons 12 and 14 in human K-ras gene and their possible mechanisms. Biochemistry 42, 10012–10023 (2003).
Chen, J. X., Zheng, Y., West, M. & Tang, M. S. Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res. 58, 2070–2075 (1998).
Feng, Z., Hu, W., Rom, W. N., Beland, F. A. & Tang, M. S. N-hydroxy-4-aminobiphenyl-DNA binding in human p53 gene: sequence preference and the effect of C5 cytosine methylation. Biochemistry 41, 6414–6421 (2002).
Denissenko, M. F., Chen, J. X., Tang, M. S. & Pfeifer, G. P. Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc. Natl Acad. Sci. USA 94, 3893–3898 (1997).
Feng, Z., Hu, W., Rom, W. N., Beland, F. A. & Tang, M. S. 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis 23, 1721–1727 (2002).
Denissenko, M. F., Pao, A., Tang, M. S. & Pfeifer, G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274, 430–432 (1996). Landmark paper in molecular epidemiology that provides an aetiological link between BP exposure and human lung cancer based on mutations at codons 157, 248 and 273 of cellular TP53.
Denissenko, M. F., Pao, A., Pfeifer, G. P. & Tang, M. S. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 16, 1241–1247 (1998).
Hecht, S. S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nature Rev. Cancer 3, 733–744 (2003).
International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Volume 83. Tobacco Smoke and Involuntary Smoking. (IARC Press, Lyon, 2004).
Hu, W., Feng, Z. & Tang, M. S. Nickel (II) enhances benzo[a]pyrene diol epoxide-induced mutagenesis through inhibition of nucleotide excision repair in human cells: a possible mechanism for nickel (II)-induced carcinogenesis. Carcinogenesis 25, 455–462 (2004).
Buterin, T. et al. Trapping of DNA nucleotide excision repair factors by nonrepairable carcinogen adducts. Cancer Res. 62, 4229–4235 (2002). Demonstrates that the NER-catalysed excision of (+)- trans-anti -BPDE-dG fails when its deoxycytosine base pair is deleted. This is known as the 'prototypic decoy adduct'. Bulky lesions opposite deoxycytosine deletion are also normally present in cells as an intermediate after replicative bypass of AAF or BP adducts.
Lewtas, J. et al. in Methods for Genetic Risk Assessment (ed. Brusick, D. J.) 125–169 (Lewis Publishers, Boca Raton, Florida, 1994).
Calabrese, E. J. & Baldwin, L. A. Toxicology rethinks its central belief. Nature 421, 691–692 (2003).
Farmer, P. B. & Shuker, D. E. G. What is the significance of increases in background levels of carcinogen-derived protein and DNA adducts? Some considerations for incremental risk assessment. Mutat. Res. 424, 275–286 (1999).
Wiltse, J. A. & Dellarco, V. L. U. S. Environmental Protection Agency's revised guidelines for carcinogen risk assessment: evaluating a postulated mode of carcinogen action in guiding dose–response extrapolation. Mutat. Res. 464, 105–115 (2000).
Henderson, L., Albertini, S. & Aardema, M. Thresholds in genotoxicity responses. Mutat. Res. 464, 123–128 (2000).
Nuwaysir, E. F., Bittner, M., Trent, J., Barrett, J. C. & Afshari, C. A. Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinog. 24, 153–159 (1999). Discussion of the advantages of cDNA microarray-based expression profiling as a highly sensitive marker for detection, monitoring and characterization of biohazardous compounds in the human environment ('ToxChip' technology).
Hamadeh, H. K. et al. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67, 232–240 (2002).
Gonzalez, F. J. The role of carcinogen-metabolizing enzyme polymorphism in cancer susceptibility. Reprod. Toxicol. 11, 397–412 (1997).
Vineis, P. Individual susceptibility to carcinogens. Oncogene, 23, 6477–6483 (2004).
Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33 (Suppl.), 238–244 (2000).
Boyland, E. History and future of chemical carcinogenesis. Br. Med. Bull. 36, 5–10 (1980).
Tsutsui, H. Über das künstlich erzeugte Cancroid bei der Maus. Gann 12, 17–21 (1918).
Bloch, B. & Dreifuss, W. Ueber die experimentelle Erzeugung von Carcinomen mit Lymphdrüsen- und Lungenmetastasen durch Teerbestandteile. Schweiz. Med. Wochenschr. 51, 1033–1037 (1921).
Leitch, A. & Kennaway, E. L. Experimental production of cancer by arsenic. Br. Med. J. II, 1107–1108 (1922).
Friedewald, W. F. & Rous, P. The initiating and promoting elements in tumor production. An analysis of the effects of tar, benzpyrene, and methylcholanthrene on rabbit skin. J. Exp. Med. 80, 101–126 (1944).
Berenblum, I. & Shubik, P., A new, quantitative, approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br. J. Cancer 1, 383–391 (1947).
I am very grateful to my colleague and friend G. P. Tochtrop for his critical reading of the manuscript. I also want to acknowledge the help and kind advice from J. Eckert in the 'Rare Books and Special Collections' department of the Francis A. Countway Library of Medicine, Harvard Medical School, Boston, Massachusetts. I wish to thank the staff of the Houghton Library, Harvard University, Cambridge, Massachusetts, for their help with Paracelsus' books. The work of the author was supported by the German Research Foundation.
The author declares no competing financial interests.
Having an affinity for negative charge; molecules that behave as electron acceptors.
Having an affinity for positive charge; molecules that behave as electron donors.
Hydrocarbons containing a carbon–carbon double bond; also known as alkenes.
Vesicles formed from the endoplasmatic reticulum when cells are disrupted; used in cell-free in vitro studies of biotransformation.
- MIXED-FUNCTION OXIDASES
Enzymes that catalyse oxidation–reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. Also known as monooxygenases or hydroxylases.
- CYTOCHROME P450
Haem-containing protein involved in electron-transfer reactions.
Chemical compounds that are foreign to the biological system.
Enzymatically catalysed chemical alterations of a compound that occur within living organisms or cells.
- VICINAL DIHALOALKANES
Saturated hydrocarbons containing two halogen atoms (for example, chlorine) that are bonded to adjacent carbon atoms.
Molecules that have two-dimensional structures.
A chemical reaction in which an oxygen is joined to an olefinic molecule to form a cyclic, three-membered ether. The products are known as oxiranes, epoxides or simply oxides.
- GENOTOXIC CARCINOGENS
Chemical carcinogens that are capable of causing damage to DNA. These can be mutagenic, clastogenic or aneugenic.
Covalent reaction products between chemicals and proteins or DNA.
Stereoisomers that are not related as mirror images to each other.
One of the two non-superimposable mirror image forms of an optically active molecule.
About this article
Cite this article
Luch, A. Nature and nurture – lessons from chemical carcinogenesis. Nat Rev Cancer 5, 113–125 (2005). https://doi.org/10.1038/nrc1546
Cancer Communications (2021)
Mutation Research/Reviews in Mutation Research (2021)
Journal of Molecular Medicine (2021)
Pharmacology & Therapeutics (2021)
Role of Base Excision Repair Pathway in the Processing of Complex DNA Damage Generated by Oxidative Stress and Anticancer Drugs
Frontiers in Cell and Developmental Biology (2021)